Filing Flows › Supernus Pharmaceuticals (SUPN) › Q3 2026 › vs Q3 2025
Supernus Pharmaceuticals (SUPN) Q3 2026 vs Q3 2025 (year over year)
Supernus Pharmaceuticals's revenue rose $34.7M (+18%) from $192M in Q3 2025 to $227M in Q3 2026. The biggest changes: Net product sales +$29.1M (+19%); ONAPGO +$10.3M (+151%); Oxtellar XR −$4.1M (-34%). Operating margin 9.3% against -31.4% (+40.7 pts).
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 9.3% | -31.4% | +40.7 pts |
| Net margin | 9.2% | -23.5% | +32.7 pts |
| Free cash flow margin | 2.8% | -32.2% | +35.0 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Qelbree | $90.8M | $81.4M | $9.4M | +12% |
| GOCOVRI | $42.6M | $40.8M | $1.8M | +4% |
| Collaboration revenue (ZURZUVAE) | $41.7M | $20.2M | $21.5M | +107% |
| Other | $3.4M | $7.0M | −$3.7M | -52% |
| Net product sales | $179M | $149M | $29.1M | +19% |
| ONAPGO | $17.1M | $6.8M | $10.3M | +151% |
| Trokendi XR | $10.2M | $10.0M | $170K | +2% |
| Oxtellar XR | $8.0M | $12.0M | −$4.1M | -34% |
| Royalty, licensing, and other revenues | $6.5M | $3.4M | $3.1M | +91% |
| APOKYN | $6.5M | $10.4M | −$3.9M | -38% |
| Revenue | $227M | $192M | $34.7M | +18% |
| Other income, net | $1.5M | $2.3M | −$747K | -33% |
| Operating profit | $21.2M | −$60.2M | $81.4M | — |
| Costs & expenses | $206M | $252M | −$46.7M | -19% |
| Pre-tax earnings | $22.7M | −$58.0M | $80.7M | — |
| Cost of revenue | $27.0M | $19.0M | $8.1M | +42% |
| Research & development | $25.8M | $29.4M | −$3.6M | -12% |
| SG&A | $128M | $180M | −$51.6M | -29% |
| Other operating costs | $24.8M | $24.3M | $437K | +2% |
| Net earnings | $20.9M | −$45.1M | $66.0M | — |
| Income tax | $1.8M | −$12.8M | $14.6M | — |
| Operating cash sources | $53.5M | −$12.5M | $66.0M | — |
| Depreciation & amortization | $23.6M | $24.8M | −$1.2M | -5% |
| Share-based compensation | $8.9M | $7.8M | $1.1M | +14% |
| Working capital & other | $46.9M | $49.2M | −$2.3M | -5% |
| Operating cash flow | $6.6M | −$61.7M | $68.3M | — |
| Free cash flow (OCF − capex) | $6.4M | −$61.8M | $68.2M | — |
| Capital expenditures | $230K | $129K | $101K | +78% |
Questions
How much did Supernus Pharmaceuticals's revenue grow year over year in Q3 2026?
Supernus Pharmaceuticals's revenue rose $34.7M (+18%) from $192M in Q3 2025 to $227M in Q3 2026.
What drove Supernus Pharmaceuticals's revenue change in Q3 2026?
Net product sales +$29.1M (+19%); ONAPGO +$10.3M (+151%); Oxtellar XR −$4.1M (-34%).